ann out : termination of funding, page-9

The Company also advises that last week it relocated its Prince Edward Island
Canadian office to Cape Breton as main operations are now based there. Pending final
licensing, the Company?s Cape Breton based pharmaceutical manufacturing business,
Stirling Pharma, is currently quoting on over 15 contract manufacturing proposals that
have approached the company. The Company advises that its Managing Director will
provide a full update of the Company?s business and its advancement and market
positioning immediately preceding the Annual Shareholders Meeting on 30 November
2010.